Literature DB >> 9661919

Positivity of the proliferation marker Ki-67 in noncycling cells.

M G van Oijen1, R H Medema, P J Slootweg, G Rijksen.   

Abstract

Ki-67 is a proliferation marker that is often used to estimate the growth fraction of tumors and other tissues. This antigen is expressed during all phases of the cell cycle but not in quiescent G0 cells. Many studies fail to indicate that the Ki-67 antigen can be expressed even when DNA synthesis is blocked. We studied the expression of the antigen Ki-67 in cycle-arrested osteosarcoma cells. We found that these cells are positive for Ki-67 even when they are arrested in G1/S or G2/M by using synchronizing inhibitors, by inducing p21(Waf1/Cip1) in a tetracycline-regulated expression system or by inducing wild type p53 and p21 after inflicting DNA damage. Our results show that not all cells containing the Ki-67 antigen are actively proliferating cells and we advise against the use of Ki-67 in studies on cells that overexpress p53 or p21.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9661919     DOI: 10.1093/ajcp/110.1.24

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  37 in total

Review 1.  Cell cycle regulation to repair the infarcted myocardium.

Authors:  Joshua D Dowell; Loren J Field; Kishore B S Pasumarthi
Journal:  Heart Fail Rev       Date:  2003-07       Impact factor: 4.214

2.  Forced expression of the cyclin B1-CDC2 complex induces proliferation in adult rat cardiomyocytes.

Authors:  Katrina A Bicknell; Carmen H Coxon; Gavin Brooks
Journal:  Biochem J       Date:  2004-09-01       Impact factor: 3.857

3.  High-level mRNA quantification of proliferation marker pKi-67 is correlated with favorable prognosis in colorectal carcinoma.

Authors:  Thomas Ihmann; Jian Liu; Wolfgang Schwabe; Peter Häusler; Detlev Behnke; Hans-Peter Bruch; Rainer Broll; Ute Windhövel; Michael Duchrow
Journal:  J Cancer Res Clin Oncol       Date:  2004-09-21       Impact factor: 4.553

4.  Beyond Dose: Using Pretherapy Biomarkers to Improve Dose Prediction of Outcomes for Radioimmunotherapy of Non-Hodgkin Lymphoma.

Authors:  Peter L Roberson; Lauren B Smith; Meredith A Morgan; Matthew J Schipper; Scott J Wilderman; Anca M Avram; Mark S Kaminski; Yuni K Dewaraja
Journal:  Cancer Biother Radiopharm       Date:  2017-10-30       Impact factor: 3.099

5.  Increased proliferation activity measured by immunoreactive Ki67 is associated with survival improvement in rectal/recto sigmoid cancer.

Authors:  Eeva Salminen; Salla Palmu; Tero Vahlberg; Peter-J Roberts; Karl-Owe Söderström
Journal:  World J Gastroenterol       Date:  2005-06-07       Impact factor: 5.742

6.  Assessment of SMAD4, p53, and Ki-67 alterations as a predictor of liver metastasis in human colorectal cancer.

Authors:  Masayo Kawakami; Tatsuro Yamaguchi; Keiichi Takahashi; Hiroshi Matsumoto; Michiya Yasutome; Shinichiro Horiguchi; Yukiko Hayashi; Nobuaki Funata; Takeo Mori
Journal:  Surg Today       Date:  2010-02-24       Impact factor: 2.549

7.  Modeling a lethal prostate cancer variant with small-cell carcinoma features.

Authors:  Vassiliki Tzelepi; Jiexin Zhang; Jing-Fang Lu; Brittany Kleb; Guanglin Wu; Xinhai Wan; Anh Hoang; Eleni Efstathiou; Kanishka Sircar; Nora M Navone; Patricia Troncoso; Shoudan Liang; Christopher J Logothetis; Sankar N Maity; Ana M Aparicio
Journal:  Clin Cancer Res       Date:  2011-12-12       Impact factor: 12.531

8.  Melanotic neuroectodermal tumour of infancy.

Authors:  Scott Hamilton; Duncan Macrae; Sumit Agrawal; Damir Matic
Journal:  Can J Plast Surg       Date:  2008

9.  Immunohistochemical Estimates of Angiogenesis, Proliferative Activity, p53 Expression, and Multiple Drug Resistance Have No Prognostic Impact in Osteosarcoma: A Comparative Clinicopathological Investigation.

Authors:  Flemming Brandt Sorensen; Kenneth Jensen; Michael Vaeth; Henrik Hager; Anette Mariane Daa Funder; Akmal Safwat; Johnny Keller; Mariann Christensen
Journal:  Sarcoma       Date:  2009-02-25

10.  Securin promotes the identification of favourable outcome in invasive breast cancer.

Authors:  K Talvinen; H Karra; S Hurme; M Nykänen; A Nieminen; J Anttinen; T Kuopio; P Kronqvist
Journal:  Br J Cancer       Date:  2009-08-18       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.